Fairvalue-Calculator Fairvalue-Calculator
EN DE

SunBio,Inc., a biotech company, (067370) Fair Value & Analysis

Healthcare · KR · Market cap 70.7B KRW

Price6,150 KRW
Fair Value4,593 KRW
Upside-25.3%
Quality91/100
Evidence: High Range 2,803 KRW – 5,741 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

SunBio,Inc., a biotech company, (067370) currently trades at 6,150 KRW, while our model-based Fair Value estimate is 4,593 KRW — implying the stock looks roughly 25.3% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

SunBio,Inc., a biotech company, develops, produces, and sells biosimilar and biopharmaceutical products, and medical devices based on its technologies of pegylation worldwide. Its biosimilar products include PEG-filgrastim; and PEG-EPO and uricase which is in preclinical stage. The company offers MucoPEG, a medical device for treatment of dry mouth syndrome; and SynoGEL, a viscosupplement for arthritic Knee. Its preclinical stage biopharmaceuticals candidates target brain stroke and chronic anemia. It also manufactures and sells PEG derivatives. The company was founded in 1997 and is headquartered in Gunpo-si, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is SunBio,Inc., a biotech company, (067370) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 4,593 KRW versus a price of 6,150 KRW — about −25% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 067370?
Our 21-model fair value for SunBio,Inc., a biotech company, is 4,593 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 6,150 KRW.
What is the quality score of 067370?
SunBio,Inc., a biotech company, has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.